Skip to content
Peptide research

FOXO4-DRI

Also known as FOXO4-D-Retro-Inverso · Proxofim
Category
Longevity & Anti-Aging
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A D-retro-inverso senolytic peptide that clears senescent cells by blocking the FOXO4-p53 interaction so p53 can trigger their self-destruction. Selective clearance has moderate support, but broader anti-aging claims rest on weak rodent and cell data with no human pharmacokinetics. The chief concern is that it manipulates p53, a key tumor suppressor, and human safety remains unknown. Supply is unregulated research-grade peptide, not an approved drug in the US.

Read Full record

Studied uses & evidence

Studied uses(8)

  • Selective senescent cell clearance

    Medium

    Multiple animal and cell studies show selective senescent-cell killing via a confirmed mechanism; no human trials.

  • Restoration of kidney function in aging

    Low

    One 2017 mouse study restored kidney markers like creatinine clearance in naturally aged animals.

  • Improved physical fitness and vitality in aged models

    Low

    One mouse study restored running capacity, coordination, and fur density across two aging models.

Evidence limits

Evidence Level
Preclinical

FOXO4-DRI has strong preclinical evidence from multiple independent labs across cell culture and animal studies, but no human clinical trials have been conducted. The original 2017 Cell paper demonstrated efficacy in three distinct mouse models (chemotoxicity, fast-aging, and natural aging). Subsequent studies have validated the approach in additional tissues including Leydig cells, chondrocytes, endothelial cells, and pulmonary fibroblasts. Second-generation variants with improved potency have been developed.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Active wound healing or surgery recovery

    High

    Senolytic action clears senescent cells needed for wound repair orchestration. May delay or impair healing.

  • Immune compromise

    High

    Rapid clearance of senescent cells may overwhelm immune clearance capacity. Apoptotic debris can trigger secondary inflammation.

  • Active cancer (p53-dependent tumors)

    Moderate

    Modulates p53 nuclear localization. Effects on p53-dependent tumor suppression are complex and unpredictable.

General cautions

  • Pregnancy

    Absolute

    Inducing apoptosis of senescent cells during pregnancy could be extremely harmful to fetal development.

Risk summary(6)

Risks = level of concern: High · Moderate · Low · Theoretical

  • All safety data from rodent studies and cell culture; no human pharmacokinetics

    High
  • Disrupts p53 dynamics; p53 is a critical tumor suppressor

    Moderate
  • Human dosing extrapolated from mouse studies

    Moderate
  • Injection site reactions

    Low
  • Full spectrum of affected tissues not characterized

    Moderate
  • Unregulated products sold online; quality varies

    High
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.